Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
about
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritisGenome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritisCD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritisPharmacogenetics and pharmacogenomics in rheumatology.Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugsRegulatory polymorphisms underlying complex disease traits.Rheumatoid arthritis in Saudi Arabia.Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritisPharmacogenetic approaches to rheumatoid arthritis.Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 yearIL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors.Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology.Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort.Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins.Genetic variation associated with preterm birth: a HuGE review.TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.Protein therapeutics: new applications for pharmacogenetics.Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid ArthritisPsoriatic arthritis: genetic susceptibility and pharmacogenetics.Cerebral small vessel disease: genetic risk assessment for prevention and treatment.Gene polymorphisms and pharmacogenetics in rheumatoid arthritisPharmacogenetics of etanercept in rheumatoid arthritis.A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.Genetic and genomic predictors of anti-TNF response.Molecular diagnostic strategies: a role in the practice of dermatology.Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.Pharmacogenomics of biological treatment in rheumatoid arthritis.Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Association of tumour necrosis factor-alpha -308 G/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis.
P2860
Q24647387-6F8C2E4D-9E73-4F08-AB75-620FA6BD35A9Q28489093-13B10269-0BBF-42BE-A376-3A3534084BC6Q28728734-B557EDBF-5A5B-4FBE-BFB3-9898126C8B19Q34070615-54D40C65-E3AC-43BE-94A7-D78FA1B19118Q34886162-95BF131F-FF51-441B-AD1A-6D33EF962947Q34896724-A486000E-DCA2-4D04-9442-C330072D0E79Q35094167-144EA555-974E-4EF1-9D86-EB1CFC643C39Q35183717-4253AB2D-7F11-48A2-BE6B-855DDFA6349CQ35555403-FAC8C9E2-306B-4368-BECF-8DF1794CDD0BQ35834289-DC3C94BF-BFF9-4342-91C9-027AF745A166Q35899269-5E9D9C2C-4AE0-4AFB-81F6-EF35AC386CEEQ35954465-A2F7888C-BC35-412A-B3B0-D0D2737A16E8Q35976402-6E08E068-DAA6-4427-B952-34F418B39932Q36189976-5C98D9BC-2263-42AA-BB0B-BF814AF87CD3Q36192796-C262F786-4B60-41FD-8866-0B18F138B1BAQ36269608-EAB6E19D-7AD3-44EC-B8DD-729A32376ECFQ36319054-FAF7CC5C-BF3B-4FD4-8508-CBD9A52EC532Q36361083-FA7B9665-1A26-495D-BC77-0F423857517AQ36441438-28FBF9A2-B5B3-40A1-816B-DC6C9A78BB7EQ36501235-1AC1E8B4-B771-463A-816A-8C66A426EFEEQ36839197-F0499380-0320-4125-9257-8F50DDE2DDC9Q36900659-5EF277EC-8D94-4888-BFFE-D66309B4A835Q36960366-7CDCA944-6391-413C-B787-602A4D0B4FADQ37000109-CC3D1D95-3C39-43A6-9E95-8DEF60A9C15BQ37041320-E83BAEB3-D79C-4359-B259-C1CF511C3C0CQ37120837-52C92C87-30C3-4B0B-A633-88A519C8AF54Q37176377-DF4E7592-0359-4A5F-9224-F50331FC7DC4Q37214931-5458E489-BFA5-4A8B-9275-3CD99EAB0544Q37235634-41928726-2D80-4BB2-9763-869DB617529BQ37470261-F50391E1-737E-4920-B8CA-8F48E2B64B0CQ37951648-CB629029-84D2-48A5-A671-228FA690834CQ38052162-79DEAEB1-9464-47D3-94BE-82253A058804Q38075774-DA032884-B5B6-4A8E-A8A3-5F7DE19AB644Q38084444-6F0D98A1-DC97-4864-B503-F032E923FF68Q38167894-6C804B54-A69E-46C8-80A0-B6A3D36D6339Q38258624-641E60C0-AA73-44A2-B918-792475F84077Q38266322-5512F9FA-C8BD-4EC6-B1E1-7B52E7FDD676Q38648460-CB9EB96A-628C-46D4-A3E1-A14AC2C291A8Q38728689-F4C3676C-E8B6-4210-966C-B4C2EF0663DFQ39272864-444416E1-0003-40C0-8FA8-CC0C98F3B485
P2860
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Genetic markers for the effica ...... erapy in rheumatoid arthritis.
@ast
Genetic markers for the effica ...... erapy in rheumatoid arthritis.
@en
type
label
Genetic markers for the effica ...... erapy in rheumatoid arthritis.
@ast
Genetic markers for the effica ...... erapy in rheumatoid arthritis.
@en
prefLabel
Genetic markers for the effica ...... erapy in rheumatoid arthritis.
@ast
Genetic markers for the effica ...... erapy in rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Genetic markers for the effica ...... erapy in rheumatoid arthritis.
@en
P2093
Andersson P
Cederholm T
Ernestam S
Heimbürger M
Hermansson Y
Lundkvist I
P2860
P304
P356
10.1136/ARD.62.6.526
P407
P577
2003-06-01T00:00:00Z